-
摘要: 肌肉病按病因可分为先天遗传性和后天获得性,临床表现并不特异,包括肌无力、肌肉萎缩、肌肉肥大、关节挛缩等,部分患者也可能会有心肌、呼吸肌、皮肤、中枢及周围神经系统等骨骼肌外受累表现。一些患者肌无力症状较轻,而关节挛缩或脊柱强直症状较明显,这一特殊表现为疾病诊断提供了线索。临床接诊时,医生需详细询问患者家族史,认真进行神经系统查体以及心肌和呼吸系统的综合评估,从而作出初步诊断; 肌电图、肌肉MRI、骨骼肌/皮肤活检和基因检测等辅助检查有助于明确诊断。本文重点介绍伴关节挛缩的遗传性肌肉病,包括胶原纤维病Ⅵ型、Emery-Dreifuss肌营养不良、SEPN1相关肌病以及FHL1相关肌病等,以提高临床对该病的认知。Abstract: Muscle disease can be divided into hereditary and acquired by pathogenesis. The clinical manifestations are unspecific, including muscle weakness, muscle hypertrophy, muscle atrophy, and joint contractures. Besides, it is likely that a spectrum of extramusclar symptoms, such as cardiac, respiratory, cutaneous, central and peripheral nervous system, may be involved. However, the specific manifestation of joint contractures or spine rigidity prevails over muscle weakness in ambulant patients and is of a high diagnostic value. To make a preliminary diagnosis, clinicians need to ask in detail about the family history and conduct a comprehensive neurological examination and a careful assessment of cardiac muscle and respiratory system. Auxiliary examinations such as electromyography, muscle MRI, biopsy of skeletal muscle or skin, and genetic test help to confirm the diagnosis. This article focuses on hereditary muscle diseases with contracture, including collagen Ⅵ-related myopathies, Emery-Dreifuss muscular dystrophies, the SEPN1 related myopathies, and FHL1 related myopathies.
-
Key words:
- joint contracture /
- muscular dystrophy /
- myopathy
利益冲突 无 -
[1] Ganetzky R, Izumi K, Edmondson A, et al. Fetal akinesia deformation sequence due to a congenital disorder of glycosylation[J]. Am J Med Genet A, 2015, 167A:2411-2417. [2] 彭晓音, 翟宇晋, 宋昉, 等.COL6A3基因变异所致VI型胶原蛋白缺乏相关肌病的临床与遗传学分析[J].中华儿科杂志, 2019, 57:136-141. doi: 10.3760/cma.j.issn.0578-1310.2019.02.014 [3] Bonnemann CG. The collagen VI-related myopathies Ullrich congenital muscular dystrophy and Bethlem myopathy[J]. Handbook Clin Neurol, 2011, 101:81-96. [4] Panadés-de Oliveira L, Rodríguez-López C, Cantero Montenegro D, et al. Bethlem myopathy: a series of 16 patients and description of seven new associated mutations[J]. J Neurol, 2019, 266:934-941. doi: 10.1007/s00415-019-09217-z [5] Allamand V, Brinas L, Richard P, et al. ColVI myopathies: where do we stand, where do we go?[J]. Skelet Muscle, 2011, 1:30. doi: 10.1186/2044-5040-1-30 [6] Hicks D, Lampe AK, Barresi R, et al. A refined diagnostic algorithm for Bethlem myopathy[J]. Neurology, 2008, 70:1192-1199. doi: 10.1212/01.wnl.0000307749.66438.6d [7] 戴毅, 易鑫, 任海涛, 等.VI型胶原蛋白相关肌病的临床特点与致病基因分析[J].中华神经科杂志, 2015, 48:974-979. doi: 10.3760/cma.j.issn.1006-7876.2015.11.008 [8] Ten Dam L, van der Kooi AJ, van Wattingen M, et al. Reliability and accuracy of skeletal muscle imaging in limb-girdle muscular dystrophies[J]. Neurology, 2012, 79:1716-1723. doi: 10.1212/WNL.0b013e31826e9b73 [9] Brull A, Morales Rodriguez B, Bonne G. The Pathogenesis and Therapies of Striated Muscle Laminopathies[J]. Front Physiol, 2018, 9:1533. doi: 10.3389/fphys.2018.01533 [10] Ghosh PS, Milone M. Clinical Reasoning: A 38-year-old woman with childhood-onset weakness[J]. Neurology, 2014, 83:e81-e84. doi: 10.1212/WNL.0000000000000698 [11] Patni N, Li XL, Adams-Huet B, et al. Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants[J]. J Clin Endocrinol Metab, 2019, 104:1099-1108. doi: 10.1210/jc.2018-01922 [12] Wang X, Zabell A, Koh W. Lamin A/C Cardiomyopathies: Current Understanding and Novel Treatment Strategies[J]. Curr Treat Options Cardiovasc Med, 2017, 19:21. doi: 10.1007/s11936-017-0520-z [13] Tan D, Yang H, Yuan Y, et al. Phenotype-Genotype Analysis of Chinese Patients with Early-Onset LMNA-Related Muscular Dystrophy[J]. PLoS One, 2015, 10:e0129699. doi: 10.1371/journal.pone.0129699 [14] Madej-Pilarczyk A.Clinical aspects of Emery-Dreifuss muscular dystrophy[J]. Nucleus, 2018, 9:268-274. [15] Malfatti E, Olivé M, Taratuto AL, et al. Skeletal Muscle Biopsy Analysis in Reducing Body Myopathy and Other FHL1-Related Disorders[J]. J Neuropathol Exp Neurol, 2013, 72:833-845. doi: 10.1097/NEN.0b013e3182a23506 [16] Schessl J, Taratuto AL, Sewry C, et al. Clinical, histolo-gical and genetic characterization of reducing body myopathy caused by mutations in FHL1[J]. Brain, 2009, 132:452-464. doi: 10.1093/brain/awn325 [17] Jokela M, Huovinen S, Palmio J, et al. Gluteus maximus hypertrophy-a diagnostic clue in four and a half lim domain 1-mutated reducing body myopathy[J]. Neuromuscul Disord, 2017, 27:962-963. doi: 10.1016/j.nmd.2017.06.014 [18] Chen DH, Raskind WH, Parson WW, et al. A novel mutation in FHL1 in a family with X-linked scapuloperoneal myopathy: phenotypic spectrum and structural study of FHL1 mutations[J]. J Neurol Sci, 2010, 296:22-29. doi: 10.1016/j.jns.2010.06.017 [19] Binder JS, Weidemann F, Schoser B, et al. Spongious hypertrophic cardiomyopathy in patients with mutations in the four-and-a-half-LIM domain 1 gene[J]. Circ Cardiovasc Gene, 2012, 5:490-502. doi: 10.1161/CIRCGENETICS.111.962332 [20] Feldkirchner S, Walter MC, Müller S, et al. Proteomic characterization of aggregate components in an intrafamilial variable FHL1-associated myopathy[J]. Neuromuscul Disord, 2013, 23:418-426. doi: 10.1016/j.nmd.2013.02.006 [21] San Román I, Navarro M, Martínez F, et al. Unclassifiable arrhythmic cardiomyopathy associated with Emery-Dreifuss caused by a mutation in FHL1[J]. Clin Genet, 2016, 90:171-176. doi: 10.1111/cge.12760 [22] Park YE, Kim DS, Shin JH.Myofibrillar myopathy caused by a novel FHL1 mutation presenting a mild myopathy with ankle contracture[J]. Clin Neurol Neurosurg, 2019, 180:48-51. doi: 10.1016/j.clineuro.2019.03.015 [23] Saini AG, Padmanabha H, Kumar S, et al. SEPN1-related Rigid Spine Muscular Dystrophy[J]. Indian J Pediatr, 2018, 85:1033-1034. doi: 10.1007/s12098-018-2713-1 [24] Ziyaee F, Shorafa E, Dastsooz H. A novel mutation in SEPN1 causing rigid spine muscular dystrophy 1: a Case report[J]. BMC Med Genet, 2019, 20:13. [25] Scoto M, Cirak S, Mein R, et al. SEPN1-related myopa-thies: clinical course in a large cohort of patients[J]. Neurology, 2011, 76:2073-2078. doi: 10.1212/WNL.0b013e31821f467c [26] Caggiano S, Khirani S, Dabaj I, et al. Diaphragmatic dysfunction in SEPN1-related myopathy[J]. Neuromuscul Disord, 2017, 27:747-755. doi: 10.1016/j.nmd.2017.04.010 [27] Varone E, Pozzer D, Di Modica S, et al. SELENON (SEPN1) protects skeletal muscle from saturated fatty acid-induced ER stress and insulin resistance[J]. Redox Biol, 2019, 24:101176. doi: 10.1016/j.redox.2019.101176
点击查看大图
计量
- 文章访问数: 1210
- HTML全文浏览量: 596
- PDF下载量: 37
- 被引次数: 0